Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
8.35 x 1 8.64 x 5
Post-market by (Cboe BZX)
8.45 -0.05 (-0.59%) 04/23/25 [NASDAQ]
8.35 x 1 8.64 x 5
Post-market 8.44 -0.01 (-0.12%) 16:29 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.36
Day High
8.76
Open 8.68
Previous Close 8.50 8.50
Volume 1,210,400 1,210,400
Avg Vol 1,752,615 1,752,615
Stochastic %K 95.56% 95.56%
Weighted Alpha +73.25 +73.25
5-Day Change +1.05 (+14.19%) +1.05 (+14.19%)
52-Week Range 3.61 - 13.85 3.61 - 13.85
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 554,047
  • Shares Outstanding, K 65,182
  • Annual Sales, $ 43,470 K
  • Annual Income, $ -17,930 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.57
  • Price/Sales 12.21
  • Price/Cash Flow N/A
  • Price/Book 5.83

Options Overview Details

View History
  • Implied Volatility 108.77% ( -2.01%)
  • Historical Volatility 127.47%
  • IV Percentile 90%
  • IV Rank 50.54%
  • IV High 180.81% on 07/08/24
  • IV Low 35.17% on 10/03/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 735
  • Volume Avg (30-Day) 3,121
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 43,905
  • Open Int (30-Day) 40,090

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.25
  • Number of Estimates 2
  • High Estimate 0.26
  • Low Estimate 0.23
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.60 +50.89%
on 04/07/25
Period Open: 10.91
11.16 -24.28%
on 03/24/25
-2.46 (-22.55%)
since 03/21/25
3-Month
5.60 +50.89%
on 04/07/25
Period Open: 12.30
12.74 -33.67%
on 01/24/25
-3.85 (-31.30%)
since 01/23/25
52-Week
3.61 +134.07%
on 08/13/24
Period Open: 5.45
13.85 -38.99%
on 10/29/24
+3.00 (+55.05%)
since 04/23/24

Most Recent Stories

More News
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated

The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78...

CRMD : 8.45 (-0.59%)
VTI : 263.44 (+1.70%)
IWM : 190.25 (+1.48%)
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

CRMD : 8.45 (-0.59%)
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

CRMD : 8.45 (-0.59%)
CorMedix (CRMD) Q4 2024 Earnings Call Transcript

CRMD earnings call for the period ending December 31, 2024.

CRMD : 8.45 (-0.59%)
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off

The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath.

CRMD : 8.45 (-0.59%)
VTI : 263.44 (+1.70%)
IWM : 190.25 (+1.48%)
CorMedix: Q4 Earnings Snapshot

CorMedix: Q4 Earnings Snapshot

CRMD : 8.45 (-0.59%)
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CRMD : 8.45 (-0.59%)
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

CRMD : 8.45 (-0.59%)
CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

CRMD : 8.45 (-0.59%)
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

Shares of CorMedix CRMD rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures.CorMedix’s Preliminary Sales Figures Beat EstimatesCorMedix reported...

CTMX : 0.7300 (-0.83%)
PBYI : 3.03 (+0.66%)
CSTL : 21.27 (-3.23%)
CRMD : 8.45 (-0.59%)

Business Summary

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed...

See More

Key Turning Points

3rd Resistance Point 9.09
2nd Resistance Point 8.92
1st Resistance Point 8.69
Last Price 8.45
1st Support Level 8.29
2nd Support Level 8.12
3rd Support Level 7.89

See More

52-Week High 13.85
Fibonacci 61.8% 9.94
Fibonacci 50% 8.73
Last Price 8.45
Fibonacci 38.2% 7.52
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective